[A phase II study of cisplatin in gastric cancer. Kyushu Cisplatin Chemotherapy Group]

A multi-institutional cooperative phase II study of cisplatin for gastric cancer was conducted. Cisplatin was administered by i.v. infusion at 70-100 mg/m2 body surface area once every 3-4 weeks. Out of 28 cases entered, 25 were evaluable. No complete response was obtained and partial responses were observed in 3 cases, the overall response rate being 12.0%. Major adverse reactions were gastrointestinal symptoms, generalized malaise, bone marrow suppression and renal disorders.